详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

185| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]BeiGene [2]Tianjin Medical University Cancer Institute and Hospital [3]Anhui Provincial Hospital,Hefei, Anhui, China, 230001 [4]The First Affiliated Hospital Of Anhui Medical University,Hefei, Anhui, China, 230022 [5]Beijing Cancer Hospital,Beijing, Beijing, China, 100142 [6]Beijing Hospital,Beijing, Beijing, China, 100730 [7]Peking Union Medical College Hospital - Oncology,Beijing, Beijing, China, 100730 [8]Beijing Friendship Hospital, Capital Medical University,Beijing, Beijing, China [9]Capital Medical University Xuanwu Hospital,Beijing, Beijing, China [10]Peking University Pepole's Hospital,Beijing, Beijing, China [11]Fujian Medical university union hospital,Fuzhou, Fujian, China, 350001 [12]Fujian Provincial Cancer Hospital,Fuzhou, Fujian, China, 350014 [13]Quanzhou First Hospital of Fujian Province,Quanzhou, Fujian, China, 362002 [14]First Affiliated Hospital of Xiamen University,Xiamen, Fujian, China, 361003 [15]Cancer Center of Guangzhou Medical University,Guangzhou, Guangdong, China, 510059 [16]Jiangmen Central Hospital,Jiangmen, Guangdong, China [17]Cancer Hospital of Shantou University Medical College - Oncology,Shantou, Guangdong, China, 515031 [18]Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College,Nanning, Guangxi, China, 530021 [19]Hainan Cancer Hospital,Haikou, Hainan, China [20]Harbin Medical University Cancer Hospital,Harbin, Heilongjiang, China, 150081 [21]Luoyang Central Hospital,Luoyang, Henan, China [22]The second affiliated hospital of Zhengzhou University,Zhengzhou, Henan, China [23]Hubei Cancer Hospital,Wuhan, Hubei, China, 430079 [24]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan, Hubei, China

研究目的：

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.